ABSTRACT
INTRODUCTION
Atherosclerosis induced retinal vein occlusion (RVO) is the second most common retinal vascular disease after diabetic retinopathy. [1] The retinal vein and artery share a common adventitial sheath at arteriovenous crossings so that atherosclerotic changes in the artery may compress the vein and precipitate RVO. [2] Homocysteine (Hcys) is a derived amino acid from dietary methionine. Hcys is either converted back to methionine by B 12 and folate or metabolized to cystathionine by B 6 . [3] Severe HHcys is rare and caused by genetic deficiencies in the enzymes cystathionine β-synthase (CBS) and methyltetrahydrofolate reductase. Mild to moderate HHcys can be caused by deficiencies in nutrients such as B 12 , B 6 and folate. [4] Hyperhomocysteinemia (HHcys) is reported as a risk factor for atherosclerosis in coronary, cerebral and retinal vasculature. [5] [6] [7] [8] There were reports in support of the hypothesis that HHcys were associated with RVO cases. [9] [10] [11] Elevated Hcys level can be lowered by folic acid supplementation. [12] But no study has done yet to see the natural course of high Hcys level following RVO. Hence our study tried to find out level of Hcys after 1 month of follow up among the RVO with HHcys at presentation.
MATERIALS AND METHOD
A 1-year prospective case-control study of consecutive, unrelated, adult patients with a diagnosis of RVO in the absence of any other local or systemic disease was conducted at the Analyser) with a Reagent kit, supplied by Lilac Clinical chemistry division. [13] (Linearity extends to 50 μmol/L).
RESULTS
The mean age of RVO patients and control participants were 48.1 ± 11.2 years and 52.2 ± 11.6 years respectively. Of the 37 RVO cases 26 patients were BRVO 10 were CRVO and 1
were HCRVO.
Hcys levels were increased significantly in the patients with RVO (mean total Hcys, 18.16 ± 4.73 μmol/L) as opposed to the control subjects (mean total Hcys, 11.05 ± 2.21 μmol/L; P < 0.001) on 2 nd day of presentation. (Table- ' †' P <0.001 as compared with Group-B.
' ‡' P <0.001 as compared with Group-B.
DISCUSSIONS
Hcys exerts its toxic effect to endothelium by reducing bioavailability of nitric oxide [14] , abnormal expression of various thrombotic factors. [15] Hcys is metabolised into hcysthiolactone that contributes to Hcys toxicity in humans. [16] (Hcys-thiolactone hypothesis)
leading to endothelial dysfunction. HHcys can lead to upregulation of the inflammatory response in the vascular smooth muscle cells causing atherosclerosis. [17] HHcys inhibits reverse cholesterol transport by reducing circulating HDL via inhibiting ApolipoproteinA-I protein synthesis. [18] HHcys was reported as an independent risk factor for RVO. [9] This study also showed that hcys levels were increased significantly in the patients with RVO as opposed to the control subjects (P < 0.001). (Table-1 predicted that this might correspond to a history or absence of history of asymptomatic myocardial ischemia. [19] Valjevac A et al have also observed two different patterns of Hcy changes in early post infarction period (Day-2 to day-5) which might reflect two distinct populations of AMI patients. Possible explanation for the observed findings could be a different genetic background, vitamin and oxidative status of patients with AMI. [20] These hypotheses did not hold true in our study. Possible explanation of such variation can be explained by the acute phase reactant property of hcys [21, 22] in group-B patients as their levels rise with acute insult and subsidies when the acute phase is over.
From this study we can conclude the elevated Hcys is not only a risk factor for RVO but also a marker of acute retinal vein occlusion hence routine therapy of Hcys lowering agents should be done judiciously in retinal vein occusion patients at presentation.
